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Average National Payments
 
To the Editor—A recent article in Value in Health
about the direct cost of rheumatoid arthritis used
the St. Anthony’s DRG Guidebook as a reference
for average national payments of hospitalizations
classified according to diagnosis-related groups
(DRGs) [1,2]. St. Anthony’s Guidebook does pro-
vide a list of DRGs with a corresponding column
called “Average National Payment.” This aver-
age national payment is calculated using an aver-
age hospital Medicare base rate of $4100 in the
1998 edition. However, we have contacted St.
Anthony Publishing to learn how the base rate
was derived. We were informed that the base rate
was not derived from nationally representative
data and that it was not intended for research
purposes.
An alternative source of cost information is the
DRG Guide prepared by the MEDSTAT
 
®
 
 Group
[3]. It consists of a table with results from their
Marketscan
 
®
 
 database of health care claims paid
by a privately insured population of approximately
seven million individuals. The average cost per DRG
in their guide represents the total amount paid for
both hospital and professional services through-
out the admission. The MEDSTAT DRG Guide
numbers differ substantially from those of the St.
Anthony’s Guidebook. For example, the cost per
case of DRG 122 (circulatory disorders with acute
myocardial infarction, without cardiovascular com-
plications, discharged alive) is $11,262.00 in the
MEDSTAT 1998 guide, but only $4692.86 in the
St. Anthony’s 1998 guide. The MEDSTAT DRG
Guide has been cited in the literature before, when
it was used in a cost-effectiveness study of statin
therapy published in Circulation [4].
The exact appropriateness of the MEDSTAT
DRG Guide depends on the specific question be-
ing researched. However, for the direct costs of
rheumatoid arthritis it may have been more suit-
able than the St. Anthony’s Guidebook, and it
may have led to higher reported costs. In future edi-
tions, the publishers of the St. Anthony’s Guide-
book should provide more information on the na-
ture of their average national payment.—Pablo
Lapuerta, MD, and Teresa Simon, MPH, Pharma-
ceutical Research Institute, Bristol-Myers Squibb.
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In Reply—Dr Lapuerta and Ms. Simon are correct
in pointing out that private sector reimbursement
rates for hospitalizations are higher than Medicare
reimbursements. In fact, there has been consider-
able lobbying of Congress to increase Medicare
reimbursements for hospitalizations, which many
hospitals believe have fallen below the cost of ser-
vice provision.
In our original analyses, we did compute hospi-
talization costs using 1994 MEDSTAT rates. Us-
ing these private sector rates would have increased
the incremental hospitalization cost of RA from
US$441 million to US$1018 million. Given that
some proportion of the population of RA patients
requiring hospitalization will be covered by Medi-
care and some by private insurance, the actual na-
tional reimbursement will be somewhere between
these two figures.
However, for this paper, we considered it criti-
cal to use a consistent set of reimbursement rates
across both inpatient and outpatient care (Medi-
care reimbursement rates) rather than mix private-
and public-sector rates. Readers should note that
for the paper we analyzed HCFA data to compute
the average reimbursement rate for physician, lab-
oratory, and other services (Medicare Part B) for
each DRG and added these to the DRG facility re-
imbursement rate reported by St. Anthony’s Guide-
book.
We have also been aware for some time of the
methodological limitations of using St. Anthony’s
estimates of Medicare reimbursement rates, which
(on the basis of our discussions with them) appear
to be derived by substituting estimated average
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hospital parameters into the HCFA-supplied soft-
ware for calculating hospital reimbursement rates.
However, the extent to which the derived esti-
mates are nationally representative is unknown. It
would be a significant service to the pharmacoeco-
nomic community if HCFA or some other entity
with access to recent Medicare data files (contain-
ing actual dates of service necessary to accurately
link inpatient physician services with hospitaliza-
tion episodes) for nonpublic use would calculate
the total reimbursements for hospitalization epi-
sodes by DRG (including costs for physician in-
patient services and any patient deductibles and
copayments) and publish those findings.—Marcia
M. Ward, PhD, Harold S. Javitz, PhD, and Ed-
ward H. Yelin, PhD.
